lutetium/neoplasms

Länken sparas på Urklipp

Välj sorteringstyp

Sida 1 från 105 resultat

Photodynamic activity of lutetium-texaphyrin in a mouse tumor system.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE New photosensitizers proposed for photodynamic therapy (PDT) treatment of tumors need to be evaluated in animal models to determine the parameters needed for treatment. They also need to be compared with existing photosensitizers for efficacy. We examined the PDT response to

Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Locally recurrent prostate cancer after treatment with radiation therapy is a clinical problem with few acceptable treatments. One potential treatment, photodynamic therapy (PDT), is a modality that uses laser light, drug photosensitizer, and oxygen to kill tumor cells through direct cellular

Phase I/II Trial of the Combination of ¹⁷⁷ Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Background: Trials of lutetium prostate specific membrane antigen (PSMA) in men with metastatic castration-resistant prostate cancer (mCRPC) have demonstrated good safety and efficacy, but combination strategies may improve outcomes.

Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE Local recurrence of rectal cancer remains a significant clinical problem despite multi-modality therapy. Photodynamic Therapy (PDT) is a cancer treatment which generates tumor kill through the production of singlet oxygen in cells containing a photosensitizing drug when exposed to laser

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine system. To estimate the clinical effectiveness of three interventions [everolimus (Afinitor®; Novartis International AG, Basel, Switzerland), lutetium-177 DOTATATE (177Lu-DOTATATE)

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

In recent years, lutetium-177 (¹⁷⁷Lu)-labeled prostate-specific membrane antigen (PSMA)-617 has become a promising new therapeutic agent in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we report on an early experience of ¹⁷⁷Lu-PSMA

A Retrospective Analysis of the Safety and Activity of Lutetium-177-PSMA Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Background: Prostate cancer is a common malignancy of the elderly, and with the aging of the population, the need is growing for therapies suitable for this age group. Lutetium-177-prostate-specific membrane antigen (Lu-PSMA), a

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Promising therapeutic results of the prostate-specific membrane antigen (PSMA) ligand have been shown when labelling with lutetium-177 (177Lu). We performed a systematic review and meta-analysis to assess the therapeutic response of 177Lu-PSMA in the treatment of metastatic castration-resistant

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

BACKGROUND

In patients with metastatic neuroendocrine neoplasms, the liver is the most commonly affected organ and a crucial factor for prognosis and survival. Peptide receptor radionuclide therapy can prolong progression-free survival in these patients. Additional treatment of

Radioactive lutetium metallofullerene 177LuxLu(3-x)N@C80-PCBPEG derivative: a potential tumor-targeted theranostic agent.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

A radioactive metallofullerene ¹⁷⁷Lu_xLu_(3-x)N@C₈₀ was firstly synthesized by means of neutron irradiation on Lu₃N@C₈₀. After modification by methoxypolyethylene glycol amine, in vivo investigation on tumor-bearing mice was performed.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Treatment with radiolabelled somatostatin analogues is a promising new tool in the management of patients with inoperable or metastasized neuroendocrine tumours. Symptomatic improvement may occur with (177)Lu-labelled somatostatin analogues that have been used for peptide receptor radionuclide

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

OBJECTIVE To establish the optimal safe dose of everolimus in combination with (177)Lu-octreotate peptide receptor radionuclide therapy (PRRT) of advanced progressive gastro-entero pancreatic neuroendocrine tumors (GEP-NETs) and to define dose-limiting toxicity. METHODS Patients with advanced

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Twelve ovarian cancer patients who failed chemotherapy entered a Phase I trial of intraperitoneal 177Lu-CC49 antibody. METHODS Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function and no previous radiation. RESULTS Side effects included mild

Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Editorial: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease.

Endast registrerade användare kan översätta artiklar

Logga in Bli medlem

Tidigare
1
2
3
4
5
6
7
Nästa

Gå med på vår
facebook-sida

Herbal & Natural Medicine

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Fungerar på 55 språk
Växtbaserade botemedel som stöds av vetenskap
Örter igenkänning av bild
Interaktiv GPS-karta - märka örter på plats (kommer snart)
Läs vetenskapliga publikationer relaterade till din sökning
Sök efter medicinska örter efter deras effekter
Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent

Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning

lutetium/neoplasms

Photodynamic activity of lutetium-texaphyrin in a mouse tumor system.

Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.

Phase I/II Trial of the Combination of 177 Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)

Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years.

A Retrospective Analysis of the Safety and Activity of Lutetium-177-PSMA Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer

Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis.

Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.

Radioactive lutetium metallofullerene 177LuxLu(3-x)N@C80-PCBPEG derivative: a potential tumor-targeted theranostic agent.

Lutetium-labelled peptides for therapy of neuroendocrine tumours.

NeuroEndocrine Tumor Therapy with Lutetium-177-octreotate and Everolimus (NETTLE): A Phase I Study.

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.

Lutetium-177 Labeled Therapeutics: ¹⁷⁷Lu-PSMA is Set to Redefine Prostate Cancer Treatment.

Editorial: Lutetium-177 Labeled Therapeutics: Emerging Importance for Cancer Treatment and Therapy of Chronic Disease.

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen

Phase I/II Trial of the Combination of ¹⁷⁷ Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)